No Data
Market Chatter: India Offers US Reciprocal Zero Tariffs on Steel, Auto Parts, Pharmaceutical Drugs
Was Jim Cramer Right About Johnson & Johnson (JNJ)?
Teva, Alvotech Get FDA Nod for Johnson & Johnson Biosimilar
Johnson & Johnson Announces New Data From Phase 3 ASTRO Study Evaluating TREMFYA Subcutaneous Induction Therapy In Adults With Ulcerative Colitis
Express News | Tremfya® (Guselkumab) Positioned to Become the First and Only Il-23 Inhibitor to Offer Subcutaneous Induction in Ulcerative Colitis as Demonstrated in New Data Through 24 Weeks
Nanobiotix Says Potential Pancreatic Cancer Treatment Extends Survival in Phase 1 Study
loading...